What is Zenrid D?
Relieving nasal and non-nasal symptoms associated with seasonal and perennial allergies such as watery or itchy eyes, runny nose, sneezing, and stuffy nose.
Zenrid D is a decongestant (Pseudoephedrine (Zenrid D)) and antihistamine (Zenrid D) combination. It works by blocking a chemical in the body, histamine, which causes allergy symptoms. It also shrinks swollen nasal passages, which relieves nasal congestion.
Zenrid D indications
Zenrid D® (Zenrid D, Pseudoephedrine (Zenrid D)) Tablets should be administered when both the antihistaminic properties of Zenrid D hydrochloride and the nasal decongestant properties of Pseudoephedrine (Zenrid D) hydrochloride are desired.
Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) Tablets are indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis in adults and children 12 years of age and older.
How should I use Zenrid D?
Use Zenrid D as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Zenrid D may be taken with or without food.
- Swallow whole. Do not crush, break, or chew before swallowing.
- If you miss a dose of Zenrid D, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Zenrid D.
Zenrid D description
Each prolonged-release tablet contains Zenrid D diHCl 5 mg and Pseudoephedrine (Zenrid D) HCl 120 mg.
It also contains the following excipients: Hydroxypropylmethylcellulose, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate, lactose monohydrate, croscarmellose sodium, titanium dioxide (E171), polyethylene glycol 400.
Zenrid D dosage
Zenrid D Dosage
Generic name: Zenrid D Hydrochloride 5mg, Pseudoephedrine (Zenrid D) Hydrochloride 120mg
Dosage form: tablet, extended release
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
- do not break or chew tablet; swallow tablet whole
| adults and children 12 years and over | take 1 tablet every 12 hours; do not take more than 2 tablets in 24 hours. |
| adults 65 years and over | ask a doctor |
| children under 12 years of age | ask a doctor |
| consumers with liver or kidney disease | ask a doctor |
More about Zenrid D (Zenrid D / Pseudoephedrine (Zenrid D))
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- 1 Review - Add your own review/rating
Consumer resources
- Zenrid D
- Other brands: All Day Allergy-D
Professional resources
- Zenrid D (FDA)
Other formulations
- Zyrtec
- Zenrid D
- Children's Zyrtec
- More (2) »
Related treatment guides
- Allergic Rhinitis
Zenrid D interactions
See also:
What other drugs will affect Zenrid D?
Zenrid D hydrochloride and Pseudoephedrine (Zenrid D) hydrochloride do not influence the pharmacokinetics of each other when administered concomitantly.
No clinically significant drug interactions have been found with Zenrid D and theophylline at a low dose, azithromycin, ketoconazole, or erythromycin. There was a small decrease in the clearance of Zenrid D caused by a 400 mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect.
Due to the Pseudoephedrine (Zenrid D) component, Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) Tablets are contraindicated in patients taking monoamine oxidase (MAO) inhibitors and for 14 days after stopping use of an MAO inhibitor. Concomitant use with antihypertensive drugs that interfere with sympathetic activity (e.g., methyldopa, mecamylamine, and reserpine) may reduce their antihypertensive effects. Increased ectopic pacemaker activity can occur when Pseudoephedrine (Zenrid D) is used concomitantly with digitalis. Care should be taken in the administration of Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) Tablets concomitantly with other sympathomimetic amines because combined effects on the cardiovascular system may be harmful to the patient.
Zenrid D side effects
See also:
What are the possible side effects of Zenrid D?
Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) Tablets
In two double-blind, placebo-controlled trials (n = 2094) in which 701 patients with seasonal allergic rhinitis were treated with Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) Tablets (Zenrid D hydrochloride 5 mg and Pseudoephedrine (Zenrid D) hydrochloride 120 mg) twice daily for two weeks, the percent of patients who withdrew prematurely due to adverse events was 2.0% in the Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) group, compared with 1.1% in the placebo group. All adverse events that were reported by greater than 1% of patients in the Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) group are listed in Table 1.
TABLE 1. ADVERSE EXPERIENCES REPORTED IN PATIENTS AGED 12 YEARS AND OLDER IN SEASONAL ALLERGIC RHINITIS TRIALS OF Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) TABLETS AT RATES OF 1% OR GREATER (PERCENT INCIDENCE)
| ADVERSE EXPERIENCE | Zenrid D | PLACEBO |
| (n = 701) | (n = 696) | |
| Insomnia | 4.0 | 0.6 |
| Dry Mouth | 3.6 | 0.4 |
| Fatigue | 2.4 | 0.9 |
| Somnolence | 1.9 | 0.1 |
| Pharyngitis | 1.7 | 1.1 |
| Epistaxis | 1.1 | 0.9 |
| Accidental Injury | 1.1 | 0.4 |
| Dizziness | 1.1 | 0.1 |
| Sinusitis | 1.0 | 0.6 |
ZYRTEC Tablets
Controlled and uncontrolled clinical trials of Zenrid D conducted in the United States and Canada included more than 6000 patients aged 12 years and older, with more than 3900 receiving Zenrid D at doses of 5 to 20 mg per day. The duration of treatment ranged from 1 week to 6 months, with a mean exposure of 30 days.
Most adverse reactions reported during therapy with Zenrid D were mild or moderate. In placebo-controlled trials, the incidence of discontinuations due to adverse reactions in patients receiving Zenrid D 5 mg or 10 mg was not significantly different from placebo (2.9% vs. 2.4%, respectively).
The most common adverse reaction in patients aged 12 years and older that occurred more frequently on Zenrid D than placebo was somnolence. The incidence of somnolence associated with Zenrid D was dose related, 6% in placebo, 11% at 5 mg and 14% at 10 mg. Discontinuations due to somnolence for Zenrid D were uncommon (1.0% on Zenrid D vs. 0.6% on placebo). Fatigue and dry mouth also appeared to be treatment-related adverse reactions. There were no differences by age, race, gender or by body weight with regard to the incidence of adverse reactions.
Table 2 lists adverse experiences in patients aged 12 years and older that were reported for Zenrid D 5 and 10 mg in controlled clinical trials in the United States and were more common with Zenrid D than placebo.
TABLE 2. ADVERSE EXPERIENCES REPORTED IN PATIENTS AGED 12 YEARS AND OLDER IN PLACEBO-CONTROLLED UNITED STATES Zenrid D TRIALS (MAXIMUM DOSE OF 10 MG) AT RATES OF 2% OR GREATER (PERCENT INCIDENCE)
| ADVERSE EXPERIENCE | Zenrid D | PLACEBO | (n=2034) | (n=1612) |
| Somnolence | 13.7 | 6.3 |
| Fatigue | 5.9 | 2.6 |
| Dry Mouth | 5.0 | 2.3 |
| Pharyngitis | 2.0 | 1.9 |
| Dizziness | 2.0 | 1.2 |
In addition, headache and nausea occurred in more than 2% of the patients, but were more common in placebo patients.
The following events were observed infrequently (less than 2%), in 3982 adults and children 12 years and older or in 659 pediatric (6 to 11 years) patients who received Zenrid D in U.S. trials, including an open study of six months duration. A causal relationship of these infrequent events with Zenrid D administration has not been established.
Autonomic Nervous System: anorexia, flushing, increased salivation, urinary retention.
Cardiovascular: cardiac failure, hypertension, palpitation, tachycardia.
Central and Peripheral Nervous Systems: abnormal coordination, ataxia, confusion, dysphonia, hyperesthesia, hyperkinesia, hypertonia, hypoesthesia, leg cramps, migraine, myelitis, paralysis, paresthesia, ptosis, syncope, tremor, twitching, vertigo, visual field defect.
Gastrointestinal: abnormal hepatic function, aggravated tooth caries, constipation, dyspepsia, eructation, flatulence, gastritis, hemorrhoids, increased appetite, melena, rectal hemorrhage, stomatitis including ulcerative stomatitis, tongue discoloration, tongue edema.
Genitourinary: cystitis, dysuria, hematuria, micturition frequency, polyuria, urinary incontinence, urinary tract infection.
Hearing and Vestibular: deafness, earache, ototoxicity, tinnitus.
Metabolic/Nutritional: dehydration, diabetes mellitus, thirst.
Musculoskeletal: arthralgia, arthritis, arthrosis, muscle weakness, myalgia.
Psychiatric: abnormal thinking, agitation, amnesia, anxiety, decreased libido, depersonalization, depression, emotional lability, euphoria, impaired concentration, insomnia, nervousness, paroniria, sleep disorder.
Respiratory System: bronchitis, dyspnea, hyperventilation, increased sputum, pneumonia, respiratory disorder, rhinitis, sinusitis, upper respiratory tract infection.
Reproductive: dysmenorrhea, female breast pain, intermenstrual bleeding, leukorrhea, menorrhagia, vaginitis.
Reticuloendothelial: lymphadenopathy.
Skin: acne, alopecia, angioedema, bullous eruption, dermatitis, dry skin, eczema, erythematous rash, furunculosis, hyperkeratosis, hypertrichosis, increased sweating, maculopapular rash, photosensitivity reaction, photosensitivity toxic reaction, pruritus, purpura, rash, seborrhea, skin disorder, skin nodule, urticaria.
Special Senses: parosmia, taste loss, taste perversion.
Vision: blindness, conjunctivitis, eye pain, glaucoma, loss of accommodation, ocular hemorrhage, xerophthalmia.
Body as a Whole: accidental injury, asthenia, back pain, chest pain, enlarged abdomen, face edema, fever, generalized edema, hot flashes, increased weight, leg edema, malaise, nasal polyp, pain, pallor, periorbital edema, peripheral edema, rigors.
Occasional instances of transient, reversible hepatic transaminase elevations have occurred during Zenrid D therapy. Hepatitis with significant transaminase elevation and elevated bilirubin in association with the use of Zenrid D has been reported.
In foreign marketing experience or experience in the post market period, the following additional rare, but potentially severe adverse events have been reported: anaphylaxis, cholestasis, glomerulonephritis, hemolytic anemia, hepatitis, orofacial dyskinesia, severe hypotension, stillbirth, thrombocytopenia, aggressive reaction and convulsions.
Pseudoephedrine (Zenrid D) Hydrochloride
Pseudoephedrine (Zenrid D) hydrochloride may cause mild CNS stimulation in hypersensitive patients.
Nervousness, excitability, restlessness, dizziness, weakness, or insomnia may occur. Headache, nausea, drowsiness, tachycardia, palpitation, pressor activity, and cardiac arrhythmias have been reported. Sympathomimetic drugs have also been associated with other untoward effects such as fear, anxiety, tenseness, tremor, hallucinations, seizures, pallor, respiratory difficulty, dysuria, and cardiovascular collapse.
Zenrid D contraindications
See also:
What is the most important information I should know about Zenrid D?
Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) Tablets are contraindicated in patients with a known hypersensitivity to any of its ingredients or to hydroxyzine.
Due to its Pseudoephedrine (Zenrid D) component, Zenrid D (Zenrid D, Pseudoephedrine (Zenrid D)) Tablets are contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment. It is also contraindicated in patients with severe hypertension, or severe coronary artery disease, and in those who have shown hypersensitivity or idiosyncrasy to its components, to adrenergic agents, or to other drugs of similar chemical structures. Manifestations of patient idiosyncrasy to adrenergic agents include insomnia, dizziness, weakness, tremor, or arrhythmias.
Active ingredient matches for Zenrid D:
| Unit description / dosage (Manufacturer) | Price, USD |
| ZENRID D TABLET 1 strip / 10 tablets each (Kaizen Pharmaceuticals Pvt Ltd) | $ 0.45 |
List of Zenrid D substitutes (brand and generic names): | |
| Tzine-X (India) | |
| Tzine-X Dextromethorphan hydrobromide10 mg, Cetirizinedihydrochloride 5 mg, Pseudoephedrine hydrochloride30 mg, Menthol 1.5 mg/5 mL. SYR / 100ml (Health Care) | $ 0.64 |
| Tzine-X Dextromethorphan hydrobromide10 mg, Cetirizinedihydrochloride 5 mg, Pseudoephedrine hydrochloride30 mg, Menthol 1.5 mg/5 mL. SYR / 60ml (Health Care) | $ 0.45 |
| 100ml (Health Care) | $ 0.64 |
| 60ml (Health Care) | $ 0.45 |
| TZINE-X syr 100ml (Health Care) | $ 0.64 |
| TZINE-X syr 60ml (Health Care) | $ 0.45 |
| Virlix D (Mexico) | |
| Virlix Plus (Spain) | |
| Virlix-D | |
| Wal-Zyr D | |
| Wintwin (India) | |
| Wintwin Paracetamol 500 mg, Pseudoephedrine hydrochloride30 mg, Cetirizinedihydrochloride 10 mg. TAB / 10 (Purewin) | $ 0.24 |
| 10's (Purewin) | $ 0.24 |
| WINTWIN tab 10's (Purewin) | $ 0.24 |
| Xeniler D (Peru) | |
| Xin Gan Ning (China) | |
| Xinase (Egypt) | |
| Zataler-D (Peru) | |
| Zetaler-D (Peru) | |
| Zetir-D | |
| Zetix-D (Peru) | |
| Zetri-D (Dominican Republic, Haiti) | |
| Zirtek Plus (Ireland) | |
| Zirtraler-D (El Salvador, Guatemala, Honduras, Nicaragua, Panama) | |
| Zyrtec Decongestant | |
| Tablet, Extended Release; Oral; Cetirizine Hydrochloride 5 mg; Pseudoephedrine Hydrochloride 120 mg | |
| Zyrtec Duo | |
| Tablet, Extended Release; Oral; Cetirizine Hydrochloride 5 mg; Pseudoephedrine Hydrochloride 120 mg | |
| Zyrtec Plus (Switzerland) | |
| Zyrtec-D (Brazil, Bulgaria, Ecuador, Hong Kong, Malaysia, Peru, Poland, Singapore, Taiwan, Thailand, United States) | |
| Tablet, Extended Release; Oral; Cetirizine Hydrochloride 5 mg; Pseudoephedrine Hydrochloride 120 mg (GlaxoSmithKline) | |
| Zyrtec-D 10 x 10's (GlaxoSmithKline) | $ 42.14 |
| Zyrtec-D 1 Blister x 10 Tablet (GlaxoSmithKline) | |
| Zyrtec-D 10 x 10's (GlaxoSmithKline) | |
| Zyrtec-D 400's (GlaxoSmithKline) | $ 168.57 |
| Zyrtec-D 10's (GlaxoSmithKline) | |
| 100 tablet in 1 bottle (GlaxoSmithKline) | |
| Zyrtec-D PR tab 10's (GlaxoSmithKline) | |
| Zyrtec-D PR tab 50's (GlaxoSmithKline) | |
| Zyrtec-D tab 10 x 10's (GlaxoSmithKline) | $ 42.14 |
| Zyrtec-D tab 400's (GlaxoSmithKline) | $ 168.57 |
| Zyrtec-D 12 Hour | |
| Tablet, Extended Release; Oral; Cetirizine Hydrochloride 5 mg; Pseudoephedrine Hydrochloride 120 mg | |
| Zyrtec-D 5 mg/120 mg (Hungary) | |
| ZyrTEC-D Allergy & Congestion | |
| Zyrtec-D PR (Cyprus) | |
See 239 substitutes for Zenrid D | |
References
- DailyMed. "PSEUDOEPHEDRINE SULFATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "PSEUDOEPHEDRINE". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Zenrid D are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Zenrid D. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yet1 consumer reported age
| Users | % | ||
|---|---|---|---|
| 30-45 | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
